Research
A scFv-based immunotoxin for selective targeting and cytotoxicity against c-Met-overexpressing cancer cells: an integrated in silico and in vitro study
Nature ·
The Brief
- The study describes a scFv-based immunotoxin designed to selectively target cancer cells that overexpress c-Met.
- The work is reported as an integrated in silico and in vitro study, so its evidence comes from computational modelling and laboratory cell experiments.
- The source summary is not available, so the reported cytotoxicity results cannot be detailed here.
Why it matters
It is an early-stage preclinical study of a targeted therapy approach against c-Met-overexpressing tumours, which science readers can use to track progress in immunotoxin design.
Who’s affected
- cancer researchers
- biomedical scientists working on targeted therapies
- #immunotoxin
- #c-met
- #targeted therapy
- #scfv
- #cancer research
- #in silico